Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Non Operating Income (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Non Operating Income for 15 consecutive years, with $930.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 64.31% year-over-year to $930.0, compared with a TTM value of $1.1 million through Sep 2025, down 14.97%, and an annual FY2024 reading of $2.6 million, down 46.37% over the prior year.
  • Non Operating Income was $930.0 for Q3 2025 at BioRestorative Therapies, up from $518.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.8 million in Q4 2022 and bottomed at -$16.4 million in Q4 2021.
  • Average Non Operating Income over 5 years is -$1.0 million, with a median of $518.0 recorded in 2025.
  • The sharpest move saw Non Operating Income crashed 16968.19% in 2023, then soared 2360.21% in 2024.
  • Year by year, Non Operating Income stood at -$16.4 million in 2021, then skyrocketed by 123.46% to $3.8 million in 2022, then tumbled by 76.16% to $916688.0 in 2023, then increased by 14.98% to $1.1 million in 2024, then crashed by 99.91% to $930.0 in 2025.
  • Business Quant data shows Non Operating Income for BRTX at $930.0 in Q3 2025, $518.0 in Q2 2025, and $1888.0 in Q1 2025.